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Background: Guidelines and experts describe 5% to 10% reductions in body weight as ‘clinically important’;
however, it is not clear if 5% to 10% weight reductions correspond to clinically important improvements in
health-related quality of life (HRQL). Our objective was to calculate the amount of weight loss required to attain
established minimal clinically important differences (MCIDs) in HRQL, measured using three validated instruments.
Methods: Data from the Alberta Population-based Prospective Evaluation of Quality of Life Outcomes and
Economic Impact of Bariatric Surgery (APPLES) study, a population-based, prospective Canadian cohort including
150 wait-listed, 200 medically managed and 150 surgically treated patients were examined. Two-year changes in
weight and HRQL measures (Short-Form (SF)-12 physical (PCS; MCID = 5) and mental (MCS; MCID = 5) component
summary score, EQ-5D Index (MCID = 0.03) and Visual Analog Scale (VAS; MCID = 10), Impact of Weight on Quality
of Life (IWQOL)-Lite total score (MCID = 12)) were calculated. Separate multivariable linear regression models were
constructed within medically and surgically treated patients to determine if weight changes achieved HRQL MCIDs.
Pooled analysis in all 500 patients was performed to estimate the weight reductions required to achieve the
pre-defined MCID for each HRQL instrument.
Results: Mean age was 43.7 (SD 9.6) years, 88% were women, 92% were white, and mean initial body mass index
was 47.9 (SD 8.1) kg/m2. In surgically treated patients (two-year weight loss = 16%), HRQL MCIDs were reached for
all instruments except the SF-12 MCS. In medically managed patients (two-year weight loss = 3%), MCIDs were
attained in the EQ-index but not the other instruments. In all patients, percent weight reductions to achieve MCIDs
were: 23% (95% confidence interval (CI): 17.5, 32.5) for PCS, 25% (17.5, 40.2) for MCS, 9% (6.2, 15.0) for EQ-Index, 23%
(17.3, 36.1) for EQ-VAS, and 17% (14.1, 20.4) for IWQOL-Lite total score.
Conclusions: Weight reductions to achieve MCIDs for most HRQL instruments are markedly higher than the
conventional threshold of 5% to 10%. Surgical, but not medical treatment, consistently led to clinically important
improvements in HRQL over two years.
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Class II (body mass index (BMI) 35 to 39.9 kg/m2) and
Class III (BMI ≥40 kg/m2) obesity (hereafter collectively
referred to as ‘severe’ obesity) have increased by 400%
over two decades and lead to substantial morbidity, mor-
tality and reduced health-related quality of life (HRQL)
[1-4]. Contemporary guidelines define 5% to 10% weight
reductions as clinically important, citing expert opinion
and statistically significant (albeit modest) improvements
in cardio-metabolic risk as evidence for this contention
[5-8]. Although many studies have examined HRQL
(perceptions of physical, mental and social functioning)
changes following weight loss [9,10], to our knowledge,
none have attempted to calculate the amount of weight
loss required to achieve minimal clinically important
differences (MCIDs) in HRQL or verify that 5% to 10%
weight reductions result in clinically important HRQL
improvements.
An MCID is the smallest difference in score in the
domain of interest which patients perceive as benefi-
cial and which would mandate a change in the patient’s
management [11,12]. HRQL, unlike various cardio-
metabolic parameters or weight, is not a surrogate or
intermediate measure; rather, it is a patient-reported
outcome of tremendous clinical importance in its own
right [8]. With the expanded use of HRQL endpoints
and the increasing number of HRQL instruments
(each with its own scoring structure and scale), interpreting
HRQL in the context of MCID improvements is impera-
tive. Thus, empirically determining the weight reduction
thresholds corresponding to these MCIDs is needed. These
instrument-specific weight loss thresholds could then
be used to assess whether new or existing treatments
are producing clinically important HRQL improvements.
The objective of this study was to examine treatment-
related HRQL change and define clinically important
weight loss as it relates to HRQL (that is, to determine the
weight reductions required to achieve HRQL MCIDs).
Specifically, we used two-year longitudinal data from
500 severely obese patients enrolled in a population-
representative bariatric program to determine: (1) the
two-year changes in weight and HRQL with medical
and surgical treatment; and (2) the amount of weight
loss required to attain MCIDs for three validated
HRQL instruments.
Methods
A detailed study protocol for the Alberta Population-based
Prospective Evaluation of the Quality of Life Outcomes and
Economic Impact of Bariatric Surgery (APPLES) study,
a prospective two-year observational evaluation of sur-
gically treated, medically managed and wait-listed se-
verely obese patients has been previously published
[13]. The University of Alberta Health Research EthicsBoard approved the study and all patients provided
written informed consent.
Participants
Patients enrolled in APPLES were recruited from the adult
specialty clinic of the Edmonton Weight Wise regional
obesity program. Weight Wise has a central, region-wide,
single-point-of-access referral system for the 1.6 million
residents of the Edmonton Zone of Alberta Health Services.
The adult specialty clinic provides both medical and surgical
treatment to practitioner-referred patients ≥18-years-old
with BMI levels ≥35 kg/m2 who have been unsuccessful with
prior attempts at managing chronic obesity. Importantly,
patients sequentially progress through the program, from
the wait-list to medical management and (if appropriate)
to surgery (approximately 65% of medically managed pa-
tients eventually receive surgery). At the time APPLES was
conducted, the mean entry wait time was two years.
APPLES was a naturalistic assessment of outcomes in
the adult clinic of Weight Wise. Patients without surgical
contraindications were enrolled. One hundred fifty patients
approved for surgery, 200 patients initiating medical man-
agement and 150 patients wait-listed were consecutively
enrolled between January 2009 and February 2010. Patients
in each study group were enrolled just after they entered
that particular phase of the program. Consistent with the
‘pragmatic’ nature of the study, no attempt was made to
delay surgery if approval was obtained. The enrollment
target was higher in the medical group to account for
expected higher attrition (due to patients’ crossing over
to surgery over the two-year period) [13,14]. Given the
sequential nature of the program, surgically treated pa-
tients would have previously received medical manage-
ment and both medical and surgical patients would
have previously been wait-listed.
Wait-listed patients were advised to attend community-
based group education sessions prior to clinic entry, but
otherwise received no specific intervention. Medically-
managed patients received at least 24 weeks of individual-
ized, intensive, lifestyle counseling (diet, exercise, behavioral
modification) based on contemporary Canadian obesity
guidelines [5]; regarding physical activity, patients were
provided individualized recommendations for how to
increase physical activity, without any formal exercise
program being initiated. Surgically-treated patients under-
went Roux-en-Y gastric bypass, gastric banding, or sleeve
gastrectomy [13,14].
Measurements
Assessments were not blinded. Baseline data included age,
sex, comorbidities, smoking status, medications, weight
and cardio-metabolic parameters [13]. Body weight was
measured as previously described [13] to the nearest
0.1 kg every six months for two years.
Warkentin et al. BMC Medicine 2014, 12:175 Page 3 of 9
http://www.biomedcentral.com/1741-7015/12/175HRQL measures
All patients completed the Short Form (SF)-12 Version
2, the EuroQoL-5 dimensions (EQ-5D), and Impact of
Weight on Quality of Life (IWQOL)-Lite surveys at the
time of entry into the cohort and every six months for
two years. These three validated instruments were chosen
to comprehensively assess HRQL outcomes, from generic
to obese-specific [15,16]. The SF-12 is a condensed ver-
sion of the SF-36, a commonly used generic health-status
tool [17]. It yields a physical and a mental health compo-
nent summary score, referred to as PCS and MCS, re-
spectively, which follow a T distribution (mean 50, SD 10),
normalized for the general US population. Higher scores
indicate better health status. A three-to-five point increase
in PCS or MCS score is considered clinically important
[18,19]. Given the severe baseline HRQL impairment
present in our population, and that larger improvements
may be expected in individuals with lower baseline scores,
we used a score of 5 as the MCID threshold [20].
The EQ-5D is a preference-based health survey assessing
five health dimensions (with three levels of problems) and
an overall health visual analog scale (EQ-VAS) [21].
The descriptive system is scored using a set of weights
representing the general population’s preferences, into
a single summary (EQ-index) anchored at 0 (death)
and 1 (full health). The EQ-VAS score ranges from 0
(worst imaginable health state) to 100 (best imaginable
health state). The established MCID for the EQ-index
score is 0.03 points, while 10 points is the MCID for
the EQ-VAS [22].
The IWQOL-Lite is used to assess obesity-specific HRQL
[23]. It consists of 31 items describing 5 domains (physical
function, self-esteem, sexual life, public distress and work).
Total scores range from 0 to 100 (with lower scores indicat-
ing greater impairment), with an MCID of 7 to 12 [12]. We
used the higher end of this range (12) as the MCID, as is
recommended if baseline HRQL impairment is severe [24].
Statistical analysis
Between-group baseline variables were compared using
one-way analysis-of-variance (ANOVA) for continuous
outcomes and chi-squared tests for dichotomous ones.
HRQL changes with medical and surgical treatment
Within-group two-year changes in weight, BMI and all
five HRQL scores were calculated. Mean wait-list sub-
tracted improvements in HRQL for medically managed
and surgically-treated patients were calculated for each
instrument, and adjusted for age, sex, baseline BMI, and
baseline HRQL score. These improvements were wait-list
adjusted to control for temporal changes in HRQL not as-
sociated with specific treatment. Proportions of medically
managed and surgically treated patients meeting the estab-
lished HRQL MCID were calculated for each instrument(wait-listed proportions are also presented). Between-group
differences in these proportions were analyzed using
chi-square tests. P-values <0.05 were considered statis-
tically significant.
Weight loss required to attain HRQL MCIDs
In all 500 participants, instrument-specific multivariable
linear regression models were constructed to determine
the independent associations between two-year changes
in weight and HRQL scores. Models were adjusted for
age, sex and baseline BMI, HRQL and study arm. The
weight change model coefficient was used to calculate
the weight loss required to achieve HRQL MCIDs for
each instrument.
In trying to conduct a modified ‘intent-to-treat’ ana-
lysis, patients were analyzed according to the group to
which they were originally allocated. Thus, once patients
transitioned from the wait-list to medical-management
or from medical-management to surgery they stopped
contributing data and were censored. As established
a priori, last-observation-carried-forward (LOCF) im-
putation for both HRQL data and weight was used to
account for data missing as a result of censoring or
loss-to-follow up [13]. Multiple imputation was not
performed because the data are not missing at ran-
dom [25]. All analyses were performed using STATA
(Version 13 SE, College Station, TX, USA).
Results
Baseline characteristics
Mean age was 43.7 (9.6) years, mean weight was 131.9
(25.1) kg, mean BMI was 47.9 (8.1) kg/m2, and 88% were
female (Table 1). Body weight and BMI were significantly
lower in the surgical group compared to the other groups
(P = 0.05 for weight and P = 0.003 for BMI). Conversely,
all HRQL scores were significantly higher in the surgical
group compared to the other groups (P <0.001 for all
comparisons).
Follow-up and missing data
At two years, weight and BMI data were 83% complete
and HRQL questionnaires were 87% complete for the SF-
12 and 89% complete for the EQ-5D and IWQOL-Lite.
Overall, 93 (62%) wait-listed patients crossed over to med-
ical management and 50 (25%) medically managed patients
crossed-over to surgery. The mean time to transition was,
on average, 22 months (SD 4) for the wait-list group and
14 months (SD 7) for the medically treated patients. No
wait-listed patients transitioned directly to surgery.
Weight change at two years
A full description has been published elsewhere [14]. Mean
two-year weight losses (SD) were 1.5 (8.5) kg or 0.9 (6.1)%
for the wait-list group, 4.1 (11.6) kg or 2.8 (8.0)% for the








Female (number (%)) 136 (91) 174 (87) 131 (87) 0.5
Age (years, mean (SD)) 43.6 (9.2) 43.9 (10.0) 43.5 (9.5) 0.9
Married (number (%)) 80 (54) 116 (58) 93 (62) 0.1
White (number (%)) 139 (93) 178 (89) 141 (94) 0.2
Weight (kg, mean (SD)) 134.7 (25.1) 132.9 (24.7) 127.9 (25.2) 0.05
BMI (kg/m2, mean (SD)) 49.4 (8.2) 48.0 (8.2) 46.2 (7.4) 0.003
Hypertension (number (%)) 99 (66) 134 (67) 92 (61) 0.5
Dyslipidemia (number (%)) 89 (59) 123 (62) 90 (60) 0.2
Diabetes (number (%)) 75 (50) 80 (40) 67 (45) 0.9
Depression (number (%)) 98 (65) 133 (67) 88 (59) 0.3
SF-12 PCS (mean (SD)) 35.5 (10.7) 37.1 (10.1) 41.5 (9.3) < 0.001
SF-12 MCS (mean (SD)) 38.5 (10.9) 40.8 (10.1) 46.9 (8.5) < 0.001
EQ-Index (mean (SD)) 0.691 (0.207) 0.716 (0.196) 0.792 (0.149) < 0.001
EQ-VAS (mean (SD)) 52.9 (22.1) 55.0 (19.4) 63.6 (18.6) < 0.001
IWQOL-lite Total Score (mean (SD)) 41.6 (21.1) 44.9 (20.4) 49.9 (19.3) < 0.001
aUsing ANOVA for continuous variables and chi-square for dichotomous variables.
BMI, body mass index; EQ-Index, EQ-5D questionnaire index score; EQ-VAS, EQ-5D questionnaire visual analog scale score; IWQOL-Lite, Impact of Weight on Quality
of Life - Lite questionnaire; MCS, mental component summary score; PCS, physical component summary score; SD, standard deviation; SF-12, Short Form
12 questionnaire.
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surgical group (P <0.001). At two years, 17%, 32% and 75%
of patients lost at least 5% of their initial body weight, and
9%, 17% and 63% lost at least 10% of their initial body
weight in the wait-listed, medically managed and surgically
treated groups, respectively (P <0.001 for all).
Instrument specific changes in HRQL over two years
Most improvements in HRQL occurred within six months
of study entry (Figure 1). At two years, the mean PCS
improved significantly more in the surgical and medical
groups compared to the wait-listed group (P <0.001 for
both comparisons) (Table 2). Surgical patients reported sta-
tistically significant (P = 0.004), but not clinically important
(2.3 points) improvements in PCS score compared to med-
ical patients. For the PCS scores, the five-point MCID was
reached in 23% of wait-listed, 46% of medically, and 54% of
surgically treated patients (P <0.001 for all groups, P = 0.12
for the medical versus surgical group) (Figure 2).
The mean MCS improved significantly in surgical
and medical groups, compared to the wait-listed group
(P = 0.003 and P <0.001, respectively), with no significant
difference between the medical and surgical groups
(P = 0.32) (Table 2). None of these differences attained
MCID thresholds. The five-point MCID was reached
for 28% of wait-listed, 42% of medically and 30% of
surgically treated patients (P = 0.01 for all groups, P = 0.02
for medical versus surgical) (Figure 2).The mean EQ-Index improved to a clinically important ex-
tent (Table 2) in the surgical and medical groups compared
to the wait-listed group (P <0.001 for both comparisons).
There was no significant difference between the medical and
surgical groups (P= 0.85). The 0.03-point MCID was reached
in 37% of wait-listed patients, 47% of medically and 44% of
surgically treated patients (P= 0.17 across all groups, P= 0.64
for surgical versus medical) (Figure 2).
The mean EQ-VAS improved in both surgical and med-
ical groups compared to the wait-listed group (P <0.001 for
both comparisons) and between surgically and medically
managed patients (P <0.001). However, none of these
reached the MCID threshold. The 10-point MCID was
reached for 37% of wait-listed patients, 50% of medically
and 56% of surgically treated patients (P = 0.003 for all
groups; P = 0.27 for surgical versus medical) (Figure 2).
Mean IWQOL-Lite total score improved in each group,
with surgical patients showing the greatest improvement
(P <0.001 for between-group comparisons; Table 2). For the
IWOQL-Lite total score, the 12-point MCID was reached
for 21% of wait-listed patients, 49% of medically and 76% of
surgically treated patients (P <0.001 for all groups; P <0.001
for surgical versus medical) (Figure 2).
Weight loss thresholds to achieve minimal important
differences in HRQL
Weight losses required to achieve the HRQL MCIDs for
each instrument (Table 3) were 23% (95% CI: 17.5, 32.5)
Figure 1 Health-related quality of life change by study group. Error bars depict ± standard error. EQ-index, EQ-5D index score; EQ-VAS,
EQ-5D visual analog scale; IWQOL-Lite, Impact of Weight on Quality of Life – Lite questionnaire; MCS, Short form-12 mental component summary
score; PCS, Short form-12 physical component summary score. *P <0.05 versus baseline.
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for the EQ-Index, 23% (17.3, 36.1) for the EQ-VAS and
17% (14.1, 20.4) for the IWQOL-Lite total score. Full
multivariable models are presented in Additional file 1:
Tables S1 to S3. No MCID thresholds were reached
with ≥5% weight loss. With ≥10% weight loss, only the EQ-
index score improvement reached the MCID threshold.
Discussion
Two major findings are noteworthy from this analysis of
500 patients enrolled in a publicly funded Canadianbariatric care program. First, compared to wait-listed
patients who lost little weight over two years, HRQL
improved following both medical and surgical treatment,
with the most clinically important improvements found
with surgery. Second, for most HRQL instruments, the per-
cent weight reductions required to achieve HRQL MCIDs
are substantially higher than currently promoted thresholds
of 5% to 10% and are more in the order of 20% or greater.
Minimum weight loss thresholds of 5% of initial body
weight are commonly cited as sufficient to improve health
[5,7]. Regulatory agencies also use a 5% placebo-subtracted
Table 2 Two-year changes in HRQL scores













subtracted)(n = 150) (n = 200) (n = 150)
SF-12 PCS 1.0 (6.7) 5.0 (7.1) 6.2 (9.2) <0.001 4.5 (2.9, 6.0) 6.8 (5.1, 8.5) 2.3 (0.7, 3.9)
SF-12 MCS 0.7 (7.7) 4.0 (9.6) 1.0 (10.6) 0.011 4.2 (2.3, 6.0) 3.2 (1.1, 5.3) −1.0 (−2.9, 0.9)
EQ-Index 0.01 (0.17) 0.07 (0.16) 0.05 (0.18) 0.002 0.07 (0.04, 0.10) 0.08 (0.04, 0.11) 0.00 (−0.03, 0.04)
EQ-VAS 5.7 (19.1) 11.1 (20.8) 12.5 (21.7) 0.009 6.9 (3.4, 10.4) 13.6 (9.7, 17.4) 6.7 (3.1, 10.2)
IWQOL-Lite Total Score 3.2 (13.8) 13.8 (15.5) 26.9 (21.4) <0.001 11.4 (8.1, 14.7) 25.7 (22.1, 29.3) 14.3 (11.0, 17.6)
aANOVA. Comparisons adjusted for age, sex, baseline BMI and baseline HRQL score. EQ-Index, Euroqol-5D questionnaire index score; EQ-VAS, Euroqol-5D
questionnaire visual analog scale score; HRQL, health-related quality of life; IWQOL-Lite, Impact of Weight on Quality of Life - Lite questionnaire; MCS, mental
component summary score; PCS, physical component summary score; SF-12, Short Form 12 questionnaire.
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of new anti-obesity drugs [26]. Our findings suggest that
this 5% threshold is not associated with clinically im-
portant improvements in HRQL in most patients. Even
10% weight loss was insufficient for most of the HRQL
instruments examined, while 20% weight reductions
appeared a more appropriate threshold to achieve clinic-
ally important HRQL improvement. A recent paper re-
ported that a 1 kg decrease in weight following a modestly
successful (5% weight loss on average) two-year behavioral
intervention was associated with statistically significant
improvements of 0.25 points in the SF-12 PCS, 0.09 points
in the SF-12 MCS, 0.54 points in EQ-VAS and 0.002 in
EQ-Index score [25,27]. Except for the MCS, these results
are similar to those reported in the present study.
The two-year HRQL changes we observed are comparable
to those reported in the Utah Obesity Study, a prospectiveFigure 2 Proportion of patients achieving MCIDs. PCS MCID = 5 points;
points; IWQOL-Lite Total Score MCID = 12 points. EQ-index, EQ-5D question
Impact of Weight on Quality of Life – Lite questionnaire; MCS, Short Form-
Form-12 questionnaire physical component summary score. *P <0.05 versucohort study that enrolled 308 surgical patients, 253
patients who sought to undergo surgery but did not
and 272 population-based controls [28]. After two years of
follow up, surgically treated patients reported clinically
important improvements in the IWQOL-Lite, PCS and
MCS scores [29]. In APPLES, surgical-treatment was
associated with the greatest improvements in HRQL
(compared to the medically managed and wait-listed
groups). HRQL improvements in medically managed
patients were surprisingly high given that relatively
modest weight losses were observed. We speculate that
provision of behavior counselling, relatively frequent
contact, and/or greater physical activity may have played a
role in improving HRQL independent of weight loss, and
further research into weight-independent and -dependent
effects is needed [30]. Wait-listed patients experienced no
change or small improvements in HRQL over two yearsMCS MCID = 5 points, EQ-Index MCID = 0.03 points; EQ-VAS MCID = 10
naire index score; EQ-VAS, EQ-5D visual analog scale; IWQOL-Lite,
12 questionnaire mental component summary score; PCS, Short
s wait-listed.
Table 3 Predicted weight loss thresholds required to achieve MCID HRQL scores
Instrument Established MCIDa Relative weight loss
required to achieve MCID
(% weight loss (95% CI))
Improvement in HRQL
achieved with 5% weight
loss (points (95% CI))
Improvement in HRQL
achieved with 10% weight
loss (points (95% CI))
SF-12 PCS 3 to 5b 23% (17.5, 32.5) 1.10 (0.77, 1.43) 2.20 (1.54, 2.86)
SF-12 MCS 3 to 5b 25% (17.6, 40.2) 1.02 (0.62, 1.42) 2.04 (1.24, 2.84)
EQ-Index 0.03 9% (6.2, 15.0) 0.017 (0.010, 0.024) 0.034 (0.020, 0.048)
EQ-VAS 10 23% (17.3, 36.1) 2.14 (1.39, 2.89) 4.28 (2.77, 5.79)
IWQOL-Lite Total Score 7 to 12b 17% (14.1, 20.4) 3.60 (2.94, 4.25) 7.19 (5.88, 8.50)
aMinimum increase in score considered to be clinically important based upon available published literature; bupper value used to estimate minimum weight loss
required to achieved MCID. CI, confidence interval; EQ-Index, EQ-5D questionnaire index score; EQ-VAS, EQ-5D questionnaire visual analog scale score; HRQL,
health-related quality of life; IWQOL-Lite, Impact of Weight on Quality of Life - Lite questionnaire; MCID, minimal clinically important difference; MCS, mental
component summary score; PCS, physical component summary score; SF-12, Short Form 12 questionnaire.
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stantial deterioration in HRQL over this time occurs in
patients awaiting bariatric care, which is relevant because
patients trying to access publicly-funded bariatric care
often face protracted wait times [31], and we can be as-
sured that at least in terms of HRQL there are no overt
harms associated with being wait-listed. In fact, there may
be small improvements associated with wait listing or,
perhaps, the HRQL changes in the wait-listed group
are a product of temporal variation.
The relatively large sample size; inclusion of surgical,
medical and wait-listed patients; long follow-up; simul-
taneous use of three validated HRQL measures; and
population-representativeness of the study sample are
major strengths of this study. However, there are several
limitations. First, the interpretation of our results relies
entirely upon the accuracy and validity of the HRQL in-
struments and established HRQL MCIDs – misidentifi-
cation of an MCID would result in misspecification of a
weight loss threshold. This may account for the discrep-
ancy between the relatively low weight losses needed to
attain EQ-5D MCIDs and those needed to attain MCIDs
with all other instruments. The 0.03 MCID for the EQ-
Index score was not derived from a population of obese
patients or patients with chronic disease and, thus, may
not appropriately generalize to our study population. In
addition, the ceiling effects commonly seen in the three
level version of the EQ-5D may make it ill-suited to as-
sess HRQL change with weight loss [30]. While there is
much debate over the appropriate ways in which to de-
termine HRQL MCIDs [12], the MCIDs for the instru-
ments we used are well-established and widely accepted,
and we conservatively predefined our MCIDs using the
higher end of the plausible ranges. Second, censoring
was high in the wait-listed and medical groups because
of the naturalistic study design in which patients were
allowed to sequentially cross over to their next treat-
ment phase. We handled this by using an intent-to-treat
framework and LOCF imputation for missing data, as is
routinely done in randomized trials of obesity management[32]. We note that study attrition was fairly low (<20%) and
LOCF imputation was mostly needed for cross-overs into
more intensive treatment (wait-listed transitioned to med-
ical management and medical to surgical treatment). LOCF
assumes that any observed changes occurring early in
follow-up are maintained over two years. This might result
in an overly optimistic assessment of treatment effective-
ness. Third, baseline between-group imbalances in weight
and HRQL were present (likely because of the sequential
nature of the data), and while we adjusted for observed dif-
ferences some residual confounding is possible. Because of
the sequential nature of the data, propensity score matching
was not used. Fourth, we did not collect data on the extent
to which health behaviors changed and, thus, could not
assess whether these contributed to weight-independent
improvements in HRQL with medical therapy. Last, our
study population was predominately white and female, and
all were severely obese, and, therefore, our results may not
generalize to a more heterogeneous population or necessar-
ily to those with lesser degrees of obesity; however, our re-
cent meta-analysis of weight loss interventions, including
participants with initial BMIs ranging between 25 kg/m2
and 55 kg/m2, showed little to no improvement in HRQL
with modest weight loss [32]. As well, Weight Wise is a
publicly funded bariatric program in one region in Canada
where all patients have universal healthcare coverage, and it
may be that we enrolled more treatment-resistant severely
obese patients than those typically seen in other studies
conducted in other settings.
Conclusions
In a severely obese population, only bariatric surgery
consistently led to statistically significant and clinically
important weight reductions. Medical-management may
have led to weight-independent HRQL improvements
and this requires further study. HRQL increments per
percent of weight loss were small and, for most severely
obese patients and most instruments, a 20% weight loss
over two years is required to achieve clinically important
HRQL improvements predictably. If replicated, these
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future non-surgical obesity treatments will need to be
more efficacious than current ones if clinically mean-
ingful HRQL improvements are to be achieved.
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